©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jul 7, 2008; 14(25): 4059-4064
Published online Jul 7, 2008. doi: 10.3748/wjg.14.4059
Published online Jul 7, 2008. doi: 10.3748/wjg.14.4059
Table 3 Underlying disease: Comparison between the rebamipide and conventional therapy groups n (%)
| Conventional group (n = 9) | Rebamipide group (n = 6) | Statistical significance | |
| Hypertension | 6 (66.7) | 2 (33.3) | NS |
| Hyperlipidemia | 0 | 3 (50.0) | NS |
| Diabetes mellitus | 1 (11.1) | 1 (16.7) | NS |
| Atrial fibrillation | 1 (11.1) | 0 | NS |
| Cerebral infarction | 1 (11.1) | 0 | NS |
| Chronic constipation | 5 (55.6) | 1 (16.7) | NS |
| Medications | |||
| Antihypertensive agents | 5 (55.6) | 1 (16.7) | NS |
| Others | 1 (11.1) | 1 (16.7) | NS |
| History of abdominal surgery | 4 (44.4) | 3 (50.0) | NS |
- Citation: Matsumoto S, Tsuji K, Shirahama S. Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: Open label study. World J Gastroenterol 2008; 14(25): 4059-4064
- URL: https://www.wjgnet.com/1007-9327/full/v14/i25/4059.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.4059